AU Patent

AU2024369988A1 — Treating pfic2 with odevixibat

Assigned to Albireo AB · Expires 2026-04-09 · 0y expired

What this patent protects

Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) including, e.g., PFIC type 2 (bile salt export pump (BSEP) deficiency), with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt there…

USPTO Abstract

Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) including, e.g., PFIC type 2 (bile salt export pump (BSEP) deficiency), with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include identifying or selecting a subject having a higher percentage of an unconjugated serum bile acid as compared to a reference level and administering an IBAT inhibitor to the identified or selected subject.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024369988A1
Jurisdiction
AU
Classification
—
Expires
2026-04-09
Drug substance claim
No
Drug product claim
No
Assignee
Albireo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.